ATHITHAN RATTANABURI

Dr. ATHITHAN RATTANABURI

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
KMKan Muadtongon
Kan Muadtongon
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
TAThiti Ajimakul
Thiti Ajimakul
YSYuthasak Suphasynth
Yuthasak Suphasynth
IJIngporn Jiamset
Ingporn Jiamset
SPSavitree Pranpanus
Savitree Pranpanus

13 July 2015 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
SBSathana Boonyapipat
Sathana Boonyapipat
YSYuthasak Supasinth
Yuthasak Supasinth
An hCG regression curve has been used to predict the natural history and response to chemotherapy in gestational trophoblastic disease. We constructed hCG regression curves in high-risk gestational trophoblastic neoplasia (GTN) treated with EMA/CO and identified an optimal hCG level to detect EMA/CO resistance in GTN. Eighty-one women with GTN treated with EMA/CO were classified as primary high-risk GTN (n=65) and single agent-resistance GTN (n=16). The hCG levels prior to each course of chemotherapy were plotted in the 10th, 50th, and 90th percentiles to construct the hCG regression curves. Diagnostic performance was evaluated for an optimal cut-off value. The median hCG levels were 264,482 mIU/mL mIU/mL and 495.5 mIU/mL mIU/mL for primary high-risk GTN and single agent-resistance GTN, respectively. The 50th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 4th and the 2nd course of chemotherapy, respectively. The 90th percentile of the hCG level in primary high-risk GTN and single agent-resistance turned to normal before the 9th and the 2nd course of chemotherapy, respectively. The hCG level of ≥118.6 mIU/mL mIU/mL at the 5thcourse of EMA/CO predicted the EMA/CO resistance in primary high-risk GTN patients with a sensitivity of 85.7% and a specificity of 100%. EMA/CO resistance in primary high-risk GTN can be predicted by using an hCG regression curve in combination with the cut-off value of 118.6 mIU/mL at the 5thcourse of chemotherapy.

15 March 2022 in Obstetrics & Gynecology Science
Verified
Journal Article
Open access
PDF file
WHWikanda Hemman
Wikanda Hemman
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
ObjectiveWe aimed to study the incidence and predictive factors of recurrent clear cell ovarian carcinoma (CCC) and evaluate the oncological outcomes after recurrence.MethodsThis was a retrospective study of 134 CCC cases diagnosed between 2005 and 2020. Clinicopathological data and oncological outcomes were extracted and evaluated. Patients with co-malignancy, mixed pathological type, or incomplete data were excluded. Descriptive statistics, univariate and multivariable analyses, and Kaplan-Meier survival probability estimates were completed. A proportional hazards model was used to assess the association between the prognostic factors with progression-free survival (PFS), overall survival (OS), and post-recurrence survival.ResultsA total of 134 patients with CCC were enrolled. The incidence of recurrent CCC was 33.6% (45/134). The median PFS was 12.8 months (95% confidence interval [CI], 9.66-18.9) in the recurrence group and 3.3 months (95% CI, 1.15-4.4) in the refractory group. Residual tumor from surgical outcome, ascites cytology, and lymphovascular space invasion (LVSI) were independent prognostic factors for PFS. The significant variables were residual tumor (sub-optimal surgery vs. optimal surgery) (hazard ratio [HR], 2.68; 95% CI, 1.48-4.87; P=0.002), ascites cytology (positive vs. negative) (HR, 2.8; 95% CI, 1.58-4.98; P=0.002), and LVSI (positive vs. negative) (HR, 2.14; 95% CI, 1.18-3.86; P=0.04). The median postrecurrence survival was 13.96 months (95% CI, 10.61-26.2) in the recurrence group.ConclusionCCC has a high rate of recurrence. Sub-optimal surgery, positive ascites cytology, and LVSI indicated a worse prognosis for PFS. Optimal cytoreductive surgery is an important part of primary treatment to improve survival in patients with CCC.

17 March 2023 in Case Reports in Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
ETEkasak Thiangphak
Ekasak Thiangphak
IJIngporn Jiamset
Ingporn Jiamset
PMPhawat Matemanosak
Phawat Matemanosak
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
Myomatous erythrocytosis syndrome (MES) is a rare gynecological condition, defined by the presence of the clinical triad of erythrocytosis, uterine fibroids, and normalization of red blood cell counts after the surgical removal of uterine fibroids. Herein, we report the case of a woman, in the postmenopausal stage, with the clinical triad of MES. She had a history of erythrocytosis of unknown etiology and underwent phlebotomy for a year prior to visiting our hospital. Pre-operative hemoglobin (Hb) level, hematocrit (Hct) level, and red blood cell (RBC) count were 18.1g/dL, 56.1, and 6.52 million cells/μL, respectively. She underwent exploratory laparotomy, transabdominal hysterectomy, and bilateral salpingo-oophorectomy. The operative findings revealed a large uterine myoma, and the pathology result was compatible with uterine leiomyoma. All hematologic parameters returned to the normal range on post-operative day 1. Her hematologic parameters returned to normal values 4 weeks after surgery with a Hb level of 13.5g/dL, Hct level of 41.2, and RBC count of 4.92 million cells/μL. The exact pathophysiology of this condition remains unknown. However, surgical removal of uterine myoma is the mainstay of treatment. Despite the rarity of this condition, its diagnosis should be considered in patients presenting with erythrocytosis and uterine masses.

27 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
Chaitong ChuruangsukChaitong Churuangsuk
Chaitong Churuangsuk
KKKhanin Khanungwanitkul
Khanin Khanungwanitkul
AKAnukoon Kaewborisutsakul
Anukoon Kaewborisutsakul
CKChanatthee Kitsiripant
Chanatthee Kitsiripant
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
PPPanupong Puttarak
Panupong Puttarak
Background: Enhanced Recovery After Surgery (ERAS) guidelines recommend preoperative carbohydrate loading; however, local hospitals often use syrup concentrate sweet drinks rather than specialized carbohydrate formulations. We compared gastric emptying, glycemic response, and fasting discomfort of a novel carbohydrate drink versus syrup concentrate sweet drinks. Methods: In this pilot randomized, crossover trial at Prince of Songkla University Hospital, Thailand, 16 healthy volunteers received three interventions with a 1-week washout period: novel carbohydrate drink 400 mL (C400), novel carbohydrate drink 250 mL (C250), and syrup sweet drink 250 mL (SYR). The primary outcome was gastric antral cross-sectional area (CSA) measured using ultrasonography at baseline, 10, 60, 120, and 180 min post-ingestion. Secondary outcomes included glycemic response and visual analog scales for thirst and hunger. Results: All drinks showed comparable gastric CSA, peaking at 10 min (5.5–6.5 cm2, p < 0.01) and returning to baseline by 120 min. Novel carbohydrate drinks produced higher glucose peaks at 60 min (C400: 147.4 mg/dL [28.0]; C250: 148.7 mg/dL [21.7]) than SYR (123.1 mg/dL [22.4], p = 0.006) with sustained elevation through 120 min. All drinks similarly reduced thirst and mouth dryness scores at 60 min (p < 0.05), though hunger increased progressively after 120 min across all groups. Conclusions: Both 400 mL and 250 mL volumes of novel carbohydrate drinks demonstrated safe gastric emptying profiles comparable to syrup concentrate sweet drinks while providing more sustained glycemic responses.

1 January 2018 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
TWThanita Wetcho
Thanita Wetcho
ARATHITHAN RATTANABURI
ATHITHAN RATTANABURI
KKKanet Kanjanapradit
Kanet Kanjanapradit
Wetcho T, et al. J Gynecol Oncol. 2017 Dec;29:e52. https://doi.org/10.3802/jgo.2018.29.e52